|
1
|
World Health Organization: Cancer Country
Profiles. 2014, http://www.who.int/cancer/country-profiles/chn_en.pdf
|
|
2
|
Cancer Genome Atlas Network, .
Comprehensive molecular portraits of human breast tumours. Nature.
490:61–70. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Callahan R: Genetic alterations in primary
breast cancer. Breast Cancer Res Treat. 13:191–203. 1989.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Eccles SA: The role of c-erbB-2/HER2/neu
in breast cancer progression and metastasis. J Mammary Gland Biol
Neoplasia. 6:393–406. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lemmon MA: The EGF receptor family as
therapeutic targets in breast cancer. Breast Dis. 18:33–43. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Vasan N, Yelensky R, Wang K, Moulder S,
Dzimitrowicz H, Avritscher R, Wang B, Wu Y, Cronin MT, Palmer G, et
al: A targeted next-generation sequencing assay detects a high
frequency of therapeutically targetable alterations in primary and
metastatic breast cancers: Implications for clinical practice.
Oncologist. 19:453–458. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chong CR and Jänne PA: The quest to
overcome resistance to EGFR-targeted therapies in cancer. Nat Med.
19:1389–1400. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Park HS, Jang MH, Kim EJ, Kim HJ, Lee HJ,
Kim YJ, Kim JH, Kang E, Kim SW, Kim IA and Park SY: High EGFR gene
copy number predicts poor outcome in triple-negative breast cancer.
Mod Pathol. 27:1212–1222. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cho EY, Choi YL, Han JJ, Kim KM and Oh YL:
Expression and amplification of Her2, EGFR and cyclin D1 in breast
cancer: Immunohistochemistry and chromogenic in situ hybridization.
Pathol Int. 58:17–25. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lv N, Xie X, Ge Q, Lin S, Wang X, Kong Y,
Shi H, Xie X and Wei W: Epidermal growth factor receptor in breast
carcinoma: Association between gene copy number and mutations.
Diagn Pathol. 6:1182011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lee HJ, Seo AN, Kim EJ, Jang MH, Kim YJ,
Kim JH, Kim SW, Ryu HS, Park IA, Im SA, et al: Prognostic and
predictive values of EGFR overexpression and EGFR copy number
alteration in HER2-positive breast cancer. Br J Cancer.
112:103–111. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sassen A, Rochon J, Wild P, Hartmann A,
Hofstaedter F, Schwarz S and Brockhoff G: Cytogenetic analysis of
HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients.
Breast Cancer Res. 10:R22008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zaczek A, Wełnicka-Jaśkiewicz M, Bielawski
KP, Jaśkiewicz J, Badzio A, Olszewski W, Rhone P and Jassem J: Gene
copy numbers of HER family in breast cancer. J Cancer Res Clin
Oncol. 134:271–279. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Livak and Schmittgen: Analysis of relative
gene expression data using real-time quantitative PCR and the
2-ΔΔCt method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gjerdrum LM, Sorensen BS, Kjeldsen E,
Sorensen FB, Nexo E and Hamilton-Dutoit S: Real-time quantitative
PCR of microdissected paraffin-embedded breast carcinoma: An
alternative method for HER-2/neu analysis. J Mol Diagn. 6:42–51.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bernardi CC, Ede S Ribeiro, Cavalli IJ,
Chautard-Freire-Maia EA and Souza RL: Amplification and deletion of
the ACHE and BCHE cholinesterase genes in sporadic breast cancer.
Cancer Genet Cytogenet. 197:158–165. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Park K, Han S, Shin E, Kim HJ and Kim JY:
EGFR gene and protein expression in breast cancers. Eur J Surg
Oncol. 33:956–960. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Burkhardt L, Grob TJ, Hermann I, Burandt
E, Choschzick M, Jänicke F, Müller V, Bokemeyer C, Simon R, Sauter
G, et al: Gene amplification in ductal carcinoma in situ of the
breast. Breast Cancer Res Treat. 123:757–765. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bauer KR, Brown M, Cress RD, Parise CA and
Caggiano V: Descriptive analysis of estrogen receptor
(ER)-negative, progesterone receptor (PR)-negative, and
HER2-negative invasive breast cancer, the so-called triple-negative
phenotype: A population-based study from the California cancer
Registry. Cancer. 109:1721–1728. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Brandt B, Vogt U, Schlotter CM, Jackisch
C, Werkmeister R, Thomas M, von Eiff M, Bosse U, Assmann G and
Zänker KS: Prognostic relevance of aberrations in the erbB
oncogenes from breast, ovarian, oral and lung cancers:
Double-differential polymerase chain reaction (ddPCR) for clinical
diagnosis. Gene. 159:35–42. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Nanda R: Targeting the human epidermal
growth factor receptor 2 (HER2) in the treatment of breast cancer:
Recent advances and future directions. Rev Recent Clin Trials.
2:111–116. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Belgrader P, Tanner SC, Regan JF, Koehler
R, Hindson BJ and Brown AS: Droplet digital PCR measurement of HER2
copy number alteration in formalin-fixed paraffin-embedded breast
carcinoma tissue. Clin Chem. 59:991–994. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Slamon DJ, Clark GM, Wong SG, Levin WJ,
Ullrich A and McGuire WL: Human breast cancer: Correlation of
relapse and survival with amplification of the HER-2/neu oncogene.
Science. 235:177–182. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Menard S, Fortis S, Castiglioni F, Agresti
R and Balsari A: HER2 as a prognostic factor in breast cancer.
Oncology. 61 Suppl 2:S67–S72. 2001. View Article : Google Scholar
|
|
25
|
Hoang MP, Sahin AA, Ordòñez NG and Sneige
N: HER-2/neu gene amplification compared with HER-2/neu protein
overexpression and interobserver reproducibility in invasive breast
carcinoma. Am J Clin Pathol. 113:852–859. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bhatti AB, Khan AI, Siddiqui N, Muzaffar
N, Syed AA, Shah MA and Jamshed A: Outcomes of triple-negative
versus non-triple-negative breast cancers managed with
breast-conserving therapy. Asian Pac J Cancer Prev. 15:2577–2581.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Stern DF: Tyrosine kinase signalling in
breast cancer: ErbB family receptor tyrosine kinases. Breast Cancer
Res. 2:176–183. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ge H, Gong X and Tang CK: Evidence of high
incidence of EGFRvIII expression and coexpression with EGFR in
human invasive breast cancer by laser capture microdissection and
immunohistochemical analysis. Int J Cancer. 98:357–361. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Olayioye MA: Update on HER-2 as a target
for cancer therapy: Intracellular signaling pathways of ErbB2/HER-2
and family members. Breast Cancer Res. 3:385–389. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ellis MJ: Neoadjuvant endocrine therapy
for breast cancer: Medical perspectives. Clin Cancer Res.
7:s4388–s4391. 2001.
|
|
31
|
Lemoine NR, Barnes DM, Hollywood DP,
Hughes CM, Smith P, Dublin E, Prigent SA, Gullick WJ and Hurst HC:
Expression of the ERBB3 gene product in breast cancer. Br J Cancer.
66:1116–1121. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kew TY, Bell JA, Pinder SE, Denley H,
Srinivasan R, Gullick WJ, Nicholson RI, Blamey RW and Ellis IO:
c-erbB-4 protein expression in human breast cancer. Br J Cancer.
82:1163–1170. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Nguyen PL, Taghian AG, Katz MS, Niemierko
A, Abi Raad RF, Boon WL, Bellon JR, Wong JS, Smith BL and Harris
JR: Breast cancer subtype approximated by estrogen receptor,
progesterone receptor and HER-2 is associated with local and
distant recurrence after breast-conserving therapy. J Clin Oncol.
26:2373–2378. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Li CY, Zhang S, Zhang XB, Wang P, Hou GF
and Zhang J: Clinicopathological and prognostic characteristics of
triple-negative breast cancer (TNBC) in Chinese patients: A
retrospective study. Asian Pac J Cancer Prev. 14:3779–3784. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Diver EJ, Foster R, Rueda BR and Growdon
WB: The therapeutic challenge of targeting HER2 in endometrial
cancer. Oncologist. 20:1058–1068. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Feldinger K and Kong A: Profile of
neratinib and its potential in the treatment of breast cancer.
Breast Cancer (Dove Med Press). 7:147–162. 2015.PubMed/NCBI
|
|
37
|
Black JC, Atabakhsh E, Kim J, Biette KM,
Van Rechem C, Ladd B, Burrowes PD, Donado C, Mattoo H, Kleinstiver
BP, et al: Hypoxia drives transient site-specific copy gain and
drug-resistant gene expression. Genes Dev. 29:1018–1031. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wang S, Mou Z, Ma Y, Li J, Li J, Ji X, Wu
K, Li L, Lu W and Zhou T: Dopamine enhances the response of
sunitinib in the treatment of drug-resistant breast cancer:
Involvement of eradicating cancer stem-like cells. Biochem
Pharmacol. 95:98–109. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Chiotaki R, Polioudaki H and
Theodoropoulos PA: Cancer stem cells in solid and liquid tissues of
breast cancer patients: Characterization and therapeutic
perspectives. Curr Cancer Drug Targets. 15:256–269. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhang P, Sun Y and Ma L: ZEB1: At the
crossroads of epithelial-mesenchymal transition, metastasis and
therapy resistance. Cell Cycle. 14:481–487. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Jaspers JE, Sol W, Kersbergen A, Schlicker
A, Guyader C, Xu G, Wessels L, Borst P, Jonkers J and Rottenberg S:
BRCA2-deficient sarcomatoid mammary tumors exhibit multidrug
resistance. Cancer Res. 75:732–741. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Montemurro F and Scaltriti M: Biomarkers
of drugs targeting HER-family signalling in cancer. J Pathol.
232:219–229. 2014. View Article : Google Scholar : PubMed/NCBI
|
